<DOC>
	<DOCNO>NCT00624377</DOCNO>
	<brief_summary>The purpose study monitor change health status severe COPD patient initiation Tiotropium therapy . This assessed physician ` global evaluation patient ` health status 8-point scale . This measure show correlate establish standard measure patient health relate quality life . The primary analysis trial include patient pre-treated long-acting beta-agonist establish clear efficacy signal patient population . As reality COPD treatment nowadays poly-pharmacy , secondary analysis analyse patient pretreated long-acting bronchodilator put change health status likely real world context . In parallel evaluation health status , lung function response patient assess gain establish objective measure treatment response .</brief_summary>
	<brief_title>Safety Effectiveness Spiriva COPD ( Chronic Obstructive Pulmonary Disease ) Patients Under Real Condition Usual Practice</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients confirm diagnosis COPD accord Global Initiative Chronic Obstructive Lung Disease ( GOLD ; updated 2005 ) . 2 . Patients assessed benefit intake longacting anticholinergic monotherapy addon medication . 3 . Tiotropium bromide na誰ve patient . 4 . Patients indication tiotropium bromide accord Taiwanese Spiriva速 label . Exclusion criterion : 1 . Patients contraindication tiotropium bromide use ( per Spiriva速 package insert ) . 2 . Known hypersensitivity active ingredient excipients Spiriva速 .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>